NASDAQ:AVXL Anavex Life Sciences (AVXL) Stock Forecast, Price & News $9.14 +0.04 (+0.44%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$8.92▼$9.2450-Day Range$7.66▼$9.5052-Week Range$7.36▼$15.24Volume811,391 shsAverage Volume776,034 shsMarket Capitalization$738.86 millionP/E RatioN/ADividend YieldN/APrice Target$42.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Anavex Life Sciences MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside366.1% Upside$42.60 Price TargetShort InterestBearish19.67% of Shares Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.77Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.66) to ($0.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector582nd out of 983 stocksBiological Products, Except Diagnostic Industry90th out of 164 stocks 3.4 Analyst's Opinion Consensus RatingAnavex Life Sciences has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $42.60, Anavex Life Sciences has a forecasted upside of 366.1% from its current price of $9.14.Amount of Analyst CoverageAnavex Life Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted19.67% of the outstanding shares of Anavex Life Sciences have been sold short.Short Interest Ratio / Days to CoverAnavex Life Sciences has a short interest ratio ("days to cover") of 15.9, which indicates bearish sentiment.Change versus previous monthShort interest in Anavex Life Sciences has recently increased by 10.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnavex Life Sciences does not currently pay a dividend.Dividend GrowthAnavex Life Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAnavex Life Sciences has received a 73.63% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Preclinical research services for mental health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Anavex Life Sciences is -0.83. Previous Next 2.7 News and Social Media Coverage News SentimentAnavex Life Sciences has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Anavex Life Sciences this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for AVXL on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows13 people have added Anavex Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 44% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anavex Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders11.60% of the stock of Anavex Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.22% of the stock of Anavex Life Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Anavex Life Sciences are expected to grow in the coming year, from ($0.66) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anavex Life Sciences is -13.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anavex Life Sciences is -13.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnavex Life Sciences has a P/B Ratio of 5.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Anavex Life Sciences (NASDAQ:AVXL) StockAnavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.Read More Receive AVXL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address AVXL Stock News HeadlinesMay 31, 2023 | finance.yahoo.comWall Street Analysts Think Anavex Life Sciences (AVXL) Could Surge 338.45%: Read This Before Placing a BetMay 27, 2023 | americanbankingnews.comReviewing Anavex Life Sciences (NASDAQ:AVXL) & Axcella Health (NASDAQ:AXLA)June 3, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. May 26, 2023 | msn.comUnusual Call Option Trade in Anavex Life Sciences (AVXL) Worth $160.97KMay 20, 2023 | americanbankingnews.comAnavex Life Sciences (NASDAQ:AVXL) Coverage Initiated at StockNews.comMay 17, 2023 | americanbankingnews.comHC Wainwright Analysts Lift Earnings Estimates for Anavex Life Sciences Corp. (NASDAQ:AVXL)May 11, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Anavex Life Sciences (AVXL)May 10, 2023 | finance.yahoo.comAnavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2023 Earnings Call TranscriptJune 3, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. May 9, 2023 | finanznachrichten.deAnavex Life Sciences Corp.: Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial ResultsMay 9, 2023 | finance.yahoo.comAnavex Life Sciences Reports Fiscal 2023 Second Quarter Financial ResultsMay 8, 2023 | msn.comAnavex Life Sciences Q2 2023 Earnings PreviewMay 8, 2023 | americanbankingnews.comAnavex Life Sciences (AVXL) to Release Quarterly Earnings on TuesdayMay 4, 2023 | seekingalpha.comAnavex And The Antioxidant Treatment Of Alzheimer's DiseaseMay 2, 2023 | msn.comHC Wainwright & Co. Reiterates Anavex Life Sciences (AVXL) Buy RecommendationMay 2, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Anavex Life SciencesMay 2, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: IVERIC bio (ISEE), Anavex Life Sciences (AVXL) and IMV (IMV)May 2, 2023 | finance.yahoo.comAnavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023May 1, 2023 | finance.yahoo.comAnavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of HypertensionApril 26, 2023 | americanbankingnews.comHead-To-Head Review: Fennec Pharmaceuticals (NASDAQ:FENC) & Anavex Life Sciences (NASDAQ:AVXL)April 9, 2023 | thestreet.comAnavex Life Sciences (AVXL) Stock Plummets on Possible SEC InvestigationApril 6, 2023 | seekingalpha.comBiogen And Eisai, Cassava Sciences, And Anavex: Clinical Trial Results In Need Of RevisionsApril 1, 2023 | americanbankingnews.comHC Wainwright Raises Anavex Life Sciences (NASDAQ:AVXL) Price Target to $54.00March 31, 2023 | markets.businessinsider.comAnalyst Ratings for Anavex Life SciencesMarch 30, 2023 | msn.comAnavex gains on long-term data for Parkinson’s disease therapyMarch 30, 2023 | markets.businessinsider.comWhat's Going On With Anavex Life Sciences Shares Today?March 30, 2023 | finance.yahoo.comANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease DementiaSee More Headlines AVXL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVXL Company Calendar Last Earnings5/09/2023Today6/03/2023Next Earnings (Estimated)8/08/2023Fiscal Year End9/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVXL CUSIPN/A CIK1314052 Webwww.anavex.com Phone(844) 689-3939FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Forecast$42.60 High Stock Price Forecast$80.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+366.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-36.78% Return on Assets-34.00% Debt Debt-to-Equity RatioN/A Current Ratio11.35 Quick Ratio11.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.80 per share Price / Book5.08Miscellaneous Outstanding Shares80,838,000Free Float71,461,000Market Cap$738.86 million OptionableOptionable Beta0.73 Key ExecutivesChristopher U. MisslingChairman, President, CEO & SecretaryStephan ToutainChief Operating OfficerSandra BoenischChief Financial Officer & TreasurerWalter E. KaufmannChief Scientific OfficerEdward R. HammondChief Medical OfficerKey CompetitorsImmaticsNASDAQ:IMTXREGENXBIONASDAQ:RGNXAllogene TherapeuticsNASDAQ:ALLOValnevaNASDAQ:VALNHilleVaxNASDAQ:HLVXView All CompetitorsInstitutional OwnershipProShare Advisors LLCSold 1,796 shares on 5/26/2023Ownership: 0.017%JPMorgan Chase & Co.Bought 13,748 shares on 5/18/2023Ownership: 0.071%New York State Common Retirement FundSold 9,124 shares on 5/18/2023Ownership: 0.049%Balyasny Asset Management L.P.Sold 28,706 shares on 5/16/2023Ownership: 0.037%AQR Capital Management LLCSold 12,937 shares on 5/16/2023Ownership: 0.015%View All Institutional Transactions AVXL Stock - Frequently Asked Questions Should I buy or sell Anavex Life Sciences stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVXL shares. View AVXL analyst ratings or view top-rated stocks. What is Anavex Life Sciences' stock price forecast for 2023? 4 analysts have issued 1 year target prices for Anavex Life Sciences' stock. Their AVXL share price forecasts range from $11.00 to $80.00. On average, they expect the company's stock price to reach $42.60 in the next twelve months. This suggests a possible upside of 366.1% from the stock's current price. View analysts price targets for AVXL or view top-rated stocks among Wall Street analysts. How have AVXL shares performed in 2023? Anavex Life Sciences' stock was trading at $9.26 at the beginning of 2023. Since then, AVXL shares have decreased by 1.3% and is now trading at $9.14. View the best growth stocks for 2023 here. Are investors shorting Anavex Life Sciences? Anavex Life Sciences saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 15,900,000 shares, an increase of 10.6% from the April 30th total of 14,380,000 shares. Based on an average trading volume of 1,000,000 shares, the short-interest ratio is currently 15.9 days. View Anavex Life Sciences' Short Interest. When is Anavex Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our AVXL earnings forecast. How were Anavex Life Sciences' earnings last quarter? Anavex Life Sciences Corp. (NASDAQ:AVXL) posted its quarterly earnings data on Tuesday, May, 9th. The biotechnology company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.01. What ETFs hold Anavex Life Sciences' stock? ETFs with the largest weight of Anavex Life Sciences (NASDAQ:AVXL) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB). What other stocks do shareholders of Anavex Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), LadRx (CYTR), Sanchez Energy (SN), Novavax (NVAX), Geron (GERN), VASCO Data Security International (VDSI), Sorrento Therapeutics (SRNE) and OPKO Health (OPK). What is Anavex Life Sciences' stock symbol? Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL." Who are Anavex Life Sciences' major shareholders? Anavex Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.21%), State Street Corp (7.02%), Geode Capital Management LLC (1.80%), Charles Schwab Investment Management Inc. (0.70%), Nwam LLC (0.69%) and Susquehanna International Group LLP (0.00%). Insiders that own company stock include Athanasios Skarpelos, Elliot Favus, Elliot Favus, Peter DO Donhauser and Sandra Boenisch. View institutional ownership trends. How do I buy shares of Anavex Life Sciences? Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Anavex Life Sciences' stock price today? One share of AVXL stock can currently be purchased for approximately $9.14. How much money does Anavex Life Sciences make? Anavex Life Sciences (NASDAQ:AVXL) has a market capitalization of $738.86 million. The biotechnology company earns $-47,980,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. How can I contact Anavex Life Sciences? Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The official website for the company is www.anavex.com. The biotechnology company can be reached via phone at (844) 689-3939 or via email at ir@anavex.com. This page (NASDAQ:AVXL) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.